Publication | Closed Access

MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding

Tumor BiologyNovel ReceptorMedicineMelanomaImmunologyTumor ImmunityCancer Cell BiologyLigand BindingMalignant MelanomaSystems BiologyCancer BiologyCell SignalingCancer Research